The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
Copyright © 2020 Elsevier Ltd. All rights reserved..
Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic dysregulation is frequent in MAFLD, and orchestrates many aspects of its development and progression. Furthermore, the high plasticity of epigenetic modifications in response to environmental cues renders epigenetics a novel area for therapeutic drug discovery. Over recent years, several epigenetics-based drugs and diagnostic biomarkers have entered clinical development and/or obtained regulatory approval. Here, we review recent advances in our understanding of epigenetic regulation and programming during MAFLD, including DNA methylation, histone modifications, chromatin remodelling, transcriptional control, and noncoding (nc)RNAs. We also discuss the potential translational implications and challenges of epigenetics in the context of MAFLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Trends in genetics : TIG - 36(2020), 6 vom: 04. Juni, Seite 429-441 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bayoumi, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA methylation |
|---|
| Anmerkungen: |
Date Completed 27.05.2021 Date Revised 27.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tig.2020.03.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309798922 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309798922 | ||
| 003 | DE-627 | ||
| 005 | 20231225134714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tig.2020.03.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309798922 | ||
| 035 | |a (NLM)32396836 | ||
| 035 | |a (PII)S0168-9525(20)30055-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bayoumi, Ali |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.05.2021 | ||
| 500 | |a Date Revised 27.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic dysregulation is frequent in MAFLD, and orchestrates many aspects of its development and progression. Furthermore, the high plasticity of epigenetic modifications in response to environmental cues renders epigenetics a novel area for therapeutic drug discovery. Over recent years, several epigenetics-based drugs and diagnostic biomarkers have entered clinical development and/or obtained regulatory approval. Here, we review recent advances in our understanding of epigenetic regulation and programming during MAFLD, including DNA methylation, histone modifications, chromatin remodelling, transcriptional control, and noncoding (nc)RNAs. We also discuss the potential translational implications and challenges of epigenetics in the context of MAFLD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a MAFLD | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a epigenetics | |
| 650 | 4 | |a fibrosis | |
| 650 | 7 | |a Histones |2 NLM | |
| 650 | 7 | |a RNA, Untranslated |2 NLM | |
| 700 | 1 | |a Grønbæk, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a George, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Eslam, Mohammed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in genetics : TIG |d 1987 |g 36(2020), 6 vom: 04. Juni, Seite 429-441 |w (DE-627)NLM012599492 |x 0168-9525 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2020 |g number:6 |g day:04 |g month:06 |g pages:429-441 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tig.2020.03.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2020 |e 6 |b 04 |c 06 |h 429-441 | ||